Page last updated: 2024-11-04

sulfadiazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfadiazine is a sulfonamide antibiotic that was first synthesized in the 1930s. It is effective against a wide range of bacteria, including those that cause pneumonia, meningitis, and urinary tract infections. Sulfadiazine works by inhibiting the synthesis of dihydrofolic acid, an essential nutrient for bacteria. Sulfadiazine is typically administered orally or intravenously. It is important to note that sulfadiazine can cause side effects such as allergic reactions, nausea, and vomiting. Sulfadiazine is studied extensively because it is a potent antibiotic with a long history of use. It is also a relatively inexpensive drug, making it an important treatment option for patients in developing countries. Sulfadiazine is also used in combination with other drugs to treat certain types of cancer, such as lymphoma and leukemia.'

Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

diazine : The parent structure of the diazines. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5215
CHEMBL ID439
CHEBI ID9328
SCHEMBL ID24176
MeSH IDM0020740

Synonyms (283)

Synonym
AB00052095-14
BRD-K32273377-001-05-4
crl-8131 & sulfadiazine
recombinant bactericidal/permeability-increasing protein & sulfadiazine
rbpi21 & sulfa
MLS000069423
smr000059113
a-306
pirimal
honey diazine
terfonyl
sulfadiazin
diazin
coco-diazine
di-azo-mul
sulfonsol
sulfolex
triple sulfas
cremotres
n(sup1)-2-pyrimidinylsulfanilamide
pecta-diazine, suspension
truozine
benzenesulfonamide, 4-amino-n-2-pyrimidinyl-
metha-meridiazine
pyrimidine, 2-sulfanilamido-
sulfanilamidopyrimidine
spofadrizine
sulfapyrimidine
2-sulfanilylaminopyrimidine
neazine
2-sulfapyrimidine
adiazine
trisulfapyrimidine, oral suspension
palatrize
cocodiazine
2-sulfanilamidopyrimidine
cremodiazine
wln: t6n cnj bmswr dz
adiazin
quadramoid
liquadiazine
theradiazine
pyrimal
sulfanilamide, n1-2-pyrimidinyl-
piridisir
nsc35600
thi-di-mer
debenal
quadetts
neotrizine
sulfapyrimidin
sulphadiazine
lipo-levazine
microsulfon
trisem
sulfapirimidin
sterazine
sulfose
sulfazine
deltazina
trifonamide
lipo-diazine
rp 2616
s. n. 112
sulfanilamide, n(sup 1)-2-pyrimidinyl-
codiazine
n(sup1)-2-pyrimidylsulfanilamide
nsc-35600
diazolone
sulfadiazene
sanodiazine
sulfatryl
eskadiazine
tri-sulfameth
DIVK1C_000543
KBIO1_000543
sulfadiazinum
4-amino-n-(pyrimidin-2-yl)benzenesulfonamide
CHEBI:9328 ,
n(1)-2-pyrimidinylsulfanilamide
sulfadiazina
n(1)-2-pyrimidylsulfanilamide
SPECTRUM_000986
BSPBIO_002884
PRESTWICK_428
cas-68-35-9
NCGC00016305-01
IDI1_000543
PRESTWICK2_000023
sdz ,
4-amino-n-pyrimidin-2-yl-benzenesulfonamide
2-sulfanilamido-pyrimidine
4-amino-n-2-pyrimidinylbenzenesulfonamide
BSPBIO_000085
BPBIO1_000095
PRESTWICK3_000023
OPREA1_081078
4-amino-n-2-pyrimidinyl-benzenesulfonamide
AB00052095
STK317797
C07658
sulfadiazine
68-35-9
sulfadiazine, >=99.0%
DB00359
D00587
sulfadiazine (tn)
sulfadiazine (jan/usp/inn)
NCGC00023291-03
NCGC00023291-04
sulfanilamide, n1-2(1h)-pyrimidinylidene-
a 306
sulfapyrimidin [german]
nsc 35600
sulfadiazina [inn-spanish]
n(sup 1)-2-pyrimidinylsulfanilamide
a-306 (van)
brn 0235192
ai3-01047
sulfadiazinum [inn-latin]
einecs 200-685-8
solfadiazina [dcit]
s.n. 112
2-sulfanilamidopyrimidin [german]
sulphadiazine e
diazovit
KBIOGR_000743
KBIO2_006602
KBIOSS_001466
KBIO3_002104
KBIO2_004034
KBIO2_001466
SPBIO_001417
SPECTRUM3_001362
SPECTRUM4_000342
SPECTRUM2_001319
PRESTWICK1_000023
SPBIO_002006
PRESTWICK0_000023
NINDS_000543
SPECTRUM1500546
SPECTRUM5_000992
NCGC00016305-02
HMS2092I15
HMS2090P09
4-amino-n-(2-pyrimidinyl)benzenesulfonamide
S0579
n-(2-pyrimidinyl)sulfanilamide
CHEMBL439 ,
sulfadiazine (trisulfapyrimidines)
bdbm50166571
HMS501L05
HMS1921A13
HMS1568E07
4-amino-n-pyrimidin-2-ylbenzenesulfonamide
AKOS000119073
A836115
HMS2095E07
[(4-aminophenyl)sulfonyl]pyrimidin-2-ylamine
BBL013169
nsc-757324
nsc757324
pharmakon1600-01500546
dtxcid5024130
dtxsid7044130 ,
tox21_110360
2-sulfanilamidopyrimidin
n1-2-pyrimidinylsulfanilamide
HMS2235D19
CCG-39257
NCGC00016305-06
NCGC00016305-04
NCGC00016305-05
NCGC00016305-03
FT-0674739
FT-0674741
unii-0n7609k889
0n7609k889 ,
solfadiazina
sulfadiazine [usp:inn:ban:jan]
5-25-10-00067 (beilstein handbook reference)
NCGC00016305-10
sulfadiazine [usp-rs]
sulfadiazine component of terfonyl
trisulfapyrimidines (sulfadiazine) [orange book]
sulfadiazine [usp impurity]
sulfadiazine [vandf]
lantrisul component sulfadiazine
sulfadiazine component of sulfaloid
sulfadiazine component of sulfose
sulfadiazine [mart.]
sulfadiazine component of triple sulfoid
sulfadiazine [ep monograph]
sulfadiazine [orange book]
sulfadiazine [jan]
sulfadimidine impurity b [ep impurity]
triple sulfoid component sulfadiazine
sulfadiazine component of lantrisul
sulfadiazine [usp monograph]
trisulfapyrimidines (sulfadiazine)
sulfadiazine [who-dd]
sulfadiazine [green book]
neotrizine component sulfadiazine
sulfadiazine [inn]
sulfadiazine [mi]
terfonyl component sulfadiazine
sulfaloid component sulfadiazine
sulfose component sulfadiazine
sulfadiazine component of neotrizine
EPITOPE ID:140083
S1770
HMS3371L19
HY-B0273
4-amino-n-(2-pyrimidinyl) benzenesulfonamide
4-amino-n-2-pyrimidylbenzenesulfonamide
MLS006011457
4-amino-n-(pyrimidin-2-yl)benzene-1-sulfonamide
SCHEMBL24176
KS-1144
AB00052095-13
Q-201759
AC-26817
2-(4-aminobenzenesulfonamido)pyrimidine
sulfacombin (salt/mix)
trisulfapyrimidine, oral suspension (salt/mix)
4-amino-n-(2-pyrimidinyl)benzenesulfonamide #
benzenesulfonamide, 4-amino-n-(2-pyrimidinyl)-
2-(p-aminobenzenesulfonamido)pyrimidin
n1-2-pyrimidylsulfanilamide
2-(4-aminobenzenesulfonylamino)pyrimidine
sulfadiazina reig jofre
4-[[(pyrimidin-2-yl)amino]sulfonyl]aniline
AB00052095_16
AB00052095_15
mfcd00006065
F1657-1720
sulfadiazine, certified reference material, tracecert(r)
SR-01000002973-2
sr-01000002973
sulfadiazine, united states pharmacopeia (usp) reference standard
sulfadiazine, vetranal(tm), analytical standard
HMS3655I10
sulfadiazine for identification of impurity f, european pharmacopoeia (ep) reference standard
sulfadiazine, european pharmacopoeia (ep) reference standard
sulfadiazine, pharmaceutical secondary standard; certified reference material
SR-01000002973-3
SBI-0051520.P003
141582-64-1
HMS3712E07
SW196657-3
benzenesulfonamide,4-amino-n-2-pyrimidinyl-
FT-0674740
sulfadiazine,(s)
Q2555060
sulfadiazine 100 microg/ml in acetonitrile
rp-2616
BCP12140
BRD-K32273377-001-09-6
AMY33423
4-amino-n-(2-pyrimidinyl)benzenesulfonamide, n1-(pyrimidin-2-yl)sulfanilamide
NCGC00016305-11
diazine
D92267
4-amino-n-2-pyrimidinyl benzenesulfonamide
NCGC00016305-09
sulfadiazine 1000 microg/ml in acetonitrile
EN300-19076
sulfadiazine for identification of impurity f
gtpl12635
sulfadiazine (usp-rs)
sulfadiazine (usp:inn:ban:jan)
sulfadiazine (usp impurity)
sulfadiazine (ep monograph)
sulfadiazina (inn-spanish)
sulfadiazine (mart.)
sulfadiazine (usp monograph)
sulfadiazine base
sulfadimidine impurity b (ep impurity)
sulfadiazinum (inn-latin)
4-amino-n-(2-pyrimidinyl)-1-benzenesulfonamide
GLXC-25873
720 - sulfonamides in fish
Z104472626

Research Excerpts

Overview

Sulfadiazine (SD) is a very common antibiotic widely used as human and fishery medicine. dissolved organic matter (DOM) plays a significant role in the indirect photodegradation of SD. The influence of DOM compositions on SD indirect Photodegradation is poorly understood. Sulfad Diazine is an environmental pollutant derived from abuse of antibiotics.

ExcerptReferenceRelevance
"Sulfadiazine (SD) is a common antibiotic administered to treat bacterial infections in livestock, and its fate and migration are greatly affected by dissolved organic matter (DOM). "( Simultaneous degradation of sulfadiazine and dissolved organic matter based on low-impact development facilities.
Cui, Y; Kou, Y; Xiong, S; Yan, C; Yuan, D; Zhai, L, 2023
)
2.65
"Sulfadiazine (SD) is a very common antibiotic widely used as human and fishery medicine, and dissolved organic matter (DOM) plays a significant role in the indirect photodegradation of SD; however, the influence of DOM compositions on SD indirect photodegradation is poorly understood."( Indirect photodegradation of sulfadiazine in the presence of DOM: Effects of DOM components and main seawater constituents.
Bai, Y; Che, X; Cui, Z; Li, C; Qu, K; Su, R; Zhou, Y, 2021
)
1.63
"Sulfadiazine is a bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria."( Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt.
Bostanian, LA; Graves, RA; Mandal, TK; Phan, KV; Pramar, YV,
)
1.07
"Sulfadiazine (SDZ) is a high priority sulfonamide antibiotic and was always detected in environmental samples. "( Biodegradation of sulfadiazine in microbial fuel cells: Reaction mechanism, biotoxicity removal and the correlation with reactor microbes.
Liu, P; Ma, J; Wang, L; Wu, S; Yang, T; You, L; Zhang, J; Zhang, W; Zhang, Z; Zhao, F, 2018
)
2.26
"Sulfadiazine is an environmental pollutant derived from abuse of antibiotics. "( Ratiometric fluorescence nanosensors based on core-shell structured carbon/CdTe quantum dots and surface molecularly imprinted polymers for the detection of sulfadiazine.
Cao, Y; Chen, X; Lai, Y; Luan, Y; Ni, X; Wang, N; Yang, W; Zhang, G; Zhou, Z, 2018
)
2.12
"Sulfadiazine (SDZ) is an antibiotic frequently administered to livestock, and it alters microbial communities when entering soils with animal manure, but understanding the interactions of these effects to the prevailing climatic regime has eluded researchers. "( Soil microbial community responses to antibiotic-contaminated manure under different soil moisture regimes.
Albert, A; Amelung, W; Radl, V; Reichel, R; Rosendahl, I; Schloter, M; Thiele-Bruhn, S, 2014
)
1.85
"Sulfadiazine (SD) is a classic antibiotic for intracranial infection. "( The Role of Sulfadiazine for the Treatment of Refractory Intracranial Infection.
Ding, X; Hu, G; Hu, L; Lu, Y; Zhang, C, 2015
)
2.24
"Sulfadiazine is a widely used veterinary medicine that has high potential to enter the environment, especially the soil compartment by the application of manure on agricultural land and grass land or by the deposition of dung pats on pasture. "( Sorption and desorption of sulfadiazine in soil and soil-manure systems.
Lamshöft, M; Spiteller, M; Sukul, P; Zühlke, S, 2008
)
2.09
"Sulfadiazine (SDZ) is an antibiotic frequently used in agricultural husbandry. "( Effect of sulfadiazine on abundance and diversity of denitrifying bacteria by determining nirK and nirS genes in two arable soils.
Heuer, H; Kleineidam, K; Kotzerke, A; Schloter, M; Sharma, S; Smalla, K; Thiele-Bruhn, S; Wilke, BM, 2010
)
2.21
"Sulfadiazine is an antibiotic of the sulfonamide group and is used as a veterinary drug in fish farming. "( Rapid automated method for on-site determination of sulfadiazine in fish farming: a stainless steel veterinary syringe coated with a selective membrane of PVC serving as a potentiometric detector in a flow-injection-analysis system.
Almeida, SA; Amorim, LR; Barbosa, J; Heitor, AH; Montenegro, MC; Sá, LC; Sales, MG, 2011
)
2.06
"Sulfadiazine is a sulfa drug commonly used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome (AIDS) and newborns with congenital infections. "( Update: availability of sulfadiazine--United States.
, 1993
)
2.04
"Zinc sulfadiazine is a new compound which is effective in vitro and in vivo against Pseudomonas aeruginosa infections in burned mice and rats. "( Zinc sulfadiazine for topical therapy of pseudomonas infection in burns.
Fox, CL; Modak, SM; Stanford, JW, 1976
)
1.28

Effects

ExcerptReferenceRelevance
"Sulfadiazine hydroxylamine has been postulated to be the mediator of the greatly increased rates of adverse reactions to sulfadiazine experienced by people with human immunodeficiency virus infection. "( Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism.
Unadkat, JD; Winter, HR, 2005
)
1.99

Treatment

Sulfadiazine treatment also restored the inhibitory effect of SRIH on basal adenylyl cyclase activity back to control values. Treatment with sulfad Diazine requires exquisite control of renal function, an increase in water ingestion and possibly the alcalinization of the urine.

ExcerptReferenceRelevance
"Sulfadiazine treatment also restored the inhibitory effect of SRIH on basal adenylyl cyclase activity back to control values."( Sulfadiazine partially protects the rat temporal cortex from amyloid beta peptide (25-35)-induced alterations of the somatostatinergic system.
Arilla-Ferreiro, E; Burgos-Ramos, E; Hernández-Pinto, A; Puebla-Jiménez, L, 2009
)
2.52
"Post-sulfadiazine treatment survival was enhanced in nude mice by reconstitution with either L3T4+ or Lyt-2+ cells and was reduced in euthymic mice by monoclonal antibody treatment directed at depleting either L3T4+ or Lyt-2+ cells or interleukin-2 (IL-2) or interferon-gamma (IFN-gamma)."( Response to treatment for an intracellular infection in a T cell-deficient host: toxoplasmosis in nude mice.
Hariprashad, J; Murray, HW; Teitelbaum, R, 1993
)
0.74
"Treatment with sulfadiazine, pyrimethamine, and steroids brought about a prompt resolution."( Acute acquired toxoplasmosis.
Reese, LT; Shafer, DM; Zweifach, P, 1981
)
0.6
"The treatment with sulfadiazine is associated with multiple side effects."( [Toxoplasmosis retinochorioiditis, a therapy comparison between spiramycin and pyrimethamine/sulfadiazine].
Gümbel, H; Hacker, M; Ohrloff, C; Richter, R; Richter, T, 1998
)
0.84
"Treatment with sulfadiazine requires exquisite control of renal function, an increase in water ingestion and possibly the alcalinization of the urine."( Patterns of sulfadiazine acute nephrotoxicity.
Cano, T; Clemente, L; Crespo, M; Pascual, J; Quereda, C; Rivera, M, 2000
)
1.03
"Treatment with sulfadiazine protected both mouse groups against acute fatal disease."( Infection of congenitally athymic (nude) mice with Toxoplasma gondii.
Emmerling, P; Hof, H; Höhne, K; Seeliger, HP,
)
0.47
"Treatment with sulfadiazine-trimethoprim caused serious, but reversible, allergic drug reactions in 6 Doberman Pinschers 10 to 21 days after the first drug exposure and/or within 1 hour to 10 days after reexposure. "( Sulfadiazine-induced allergy in six Doberman pinschers.
Giger, U; Gorman, NT; Millichamp, NJ; Werner, LL, 1985
)
2.06

Toxicity

Toxic effects from sulfadiazine were relatively mild and infrequent. Fenton oxidation process could remove sulfad Diazine, but also increase solution toxicity due to the presence of more toxic products.

ExcerptReferenceRelevance
" Toxic effects from sulfadiazine were relatively mild and infrequent."( Landmark article June 14, 1941: Sulfadiazine. Therapeutic evaluation and toxic effects on four hundred and forty-six patients. By Maxwell Finland, Elias Strauss, and Osler L. Peterson.
Finland, M; Peterson, OL; Strauss, E, 1984
)
0.87
" Provided prophylactic and therapeutic recommendations are complied with, outcome of this drug-related side effect is usually excellent, and rare relapses will similarly respond well."( Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome.
Becker, K; Häussinger, D; Jablonowski, H, 1996
)
1.74
" No adverse effects other than loose faeces and diarrhoea were detected."( Side effects of oral antimicrobial agents in the horse: a comparison of pivampicillin and trimethoprim/sulphadiazine.
Barneveld, A; Ensink, JM; Klein, WR; van Miert, AS; Vulto, AG, 1996
)
0.29
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The results from this study suggest that the Fenton oxidation process could remove sulfadiazine, but also increase solution toxicity due to the presence of more toxic products."( Chemical oxidation of sulfadiazine by the Fenton process: kinetics, pathways, toxicity evaluation.
Li, WJ; Xiao, AG; Yang, JF; Ying, GG; Zhou, SB, 2014
)
0.94

Pharmacokinetics

A pharmacokinetic and tissue residue study of sulfadiazine combined with trimethoprim (SDZ/TMP = 5/1) was conducted in Siniperca chuatsi after single- (120 mg/kg) or multiple-dose (an initial dose of 120mg/kg followed by a 5-day consecutive dose of 60mg/ kg) oral administrations at 28 °C. Pretreatment with allicin changed the pharmacokinetics behavior of orally administered sulf adiazine, by increasing AUC (41)

ExcerptReferenceRelevance
" In renal impairment although the serum half-life (t1/2) of both active and total SDZ remains similar to that of TMP, the t1/2 of total SMZ becomes several times higher than the t1/2 of TMP."( Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function.
Anstad, U; Bergan, T; Brodwall, EK; Vik-Mo, H, 1979
)
0.26
" The elimination half-life (beta-phase) of the sulphonamides in plasma varied from 70 to 1000 min and was positively correlated with the solubility of the compounds in organic solvents."( Half-life, apparent volume of distribution and protein-binding for some sulphonamides in cows.
Nielsen, P; Rasmussen, F, 1977
)
0.26
"The suction blister technique was used for pharmacokinetic studies with sulfonamides and trimethoprim."( Pharmacokinetic studies of antibacterial agents using the suction blister method.
Bredesen, JE; Bruun, JN; Kierulf, P; Lunde, PK, 1990
)
0.28
" Clinically important pharmacokinetic parameters of the two drugs in the three preparations were determined and compared."( A comparison of some of the pharmacokinetic parameters of three commercial sulphadiazine/trimethoprim combined preparations given orally to pigs.
Framstad, T; Odegaard, SA; Skjerve, E; Sohlberg, S; Søli, NE, 1990
)
0.28
" Both combination drugs have similar serum half-life values in persons with normal renal function (half-life of 8 to 12 hours), but the sulphamethoxazole metabolites are retained more than trimethoprim in reduced renal function."( Clinical pharmacokinetics of co-trimazine.
Bergan, T; Ortengren, B; Westerlund, D,
)
0.13
" Difference in elimination half-life of SMZ, SMR, and SDZ could be related to difference in metabolism and renal clearance values."( Pharmacokinetics and renal clearance of sulfamethazine, sulfamerazine, and sulfadiazine and their N4-acetyl and hydroxy metabolites in horses.
Baakman, M; Firth, EC; Nouws, JF; Vree, TB, 1987
)
0.5
" The elimination half-life in serum during steady state was 16."( Pharmacokinetics of oral co-trimazine and the penetration of its components sulfadiazine and trimethoprim into peripheral human lymph.
Bergan, T; Engeset, A; Olszewski, W, 1986
)
0.5
" Trimethoprim (TMP) and sulfadiazine (SDZ) concentrations in serum and synovial fluid were measured and pharmacokinetic parameters were calculated."( Pharmacokinetics of trimethoprim/sulfadiazine in neonatal calves: influence of synovitis.
Guard, CL; Schwark, WS; Schwartsman, RV; Shoaf, SE, 1986
)
0.86
"Pharmacokinetic studies in broilers and layers of different sulphonamides indicate a good absorption and a long elimination half-life (of sulphaquinoxaline, sulphadimidine and to a lesser degree sulphadiazine) resulting in high plasma concentrations during drinking water medication in the recommended therapeutic doses."( Some pharmacokinetic aspects of four sulphonamides and trimethoprim, and their therapeutic efficacy in experimental Escherichia coli infection in poultry.
de Jong, WA; Doornenbal, P; Goren, E, 1984
)
0.27
" Elimination half-life decreased from 455 min."( Pharmacokinetics and metabolism of sulphadiazine in neonatal and young pigs.
Friis, C; Gyrd-Hansen, N; Nielsen, P; Olsen, CE; Rasmussen, F, 1984
)
0.27
" Pharmacokinetic analysis was based upon "one compartment model"."( Pharmacokinetic analysis of the level of sulfonamide-trimethoprim combination in calves.
Duda, M; Roliński, Z,
)
0.13
" The TMP-SD combination showed a satisfactory clinical effect and favourable pharmacokinetic properties in children with UTI."( Clinical effect and pharmacokinetics of trimethoprim-sulphadiazine in children with urinary tract infections.
Aarbakke, J; Digranes, A; Fellner, H; Fluge, G; Høylandskjaer, A; Opshaug, O, 1983
)
0.27
" The pharmacokinetic analysis showed a plasma elimination half-life in the terminal phase of 10."( Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients.
Naber, K; Vergin, H; Weigand, W, 1981
)
0.26
" By using a 1-compartment open model, pharmacokinetic parameters for both drugs were estimated from the mean serum concentration data after oral administration."( Pharmacokinetics of trimethoprim and sulfadiazine in the dog: urine concentrations after oral administration.
Bushby, SR; DeAngelis, D; Eure, S; Ling, GV; Sigel, CW; Woolley, JL, 1981
)
0.54
" A two-compartment pharmacokinetic model was developed to describe the disposition of these drugs."( Some pharmacokinetic and biochemical aspects of sulphadiazine and sulphadimidine in ewes.
Atef, M; El-Gendi, AY; El-Sayed, MG; Salam, SA; Youssef, SA, 1981
)
0.26
" During PA infusion in rapid-acetylation rabbits, no significant changes were found in any of the pharmacokinetic parameters for SDZ."( The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits.
Ho, Y; Hsu, KY; Song, DJ, 1995
)
0.29
" Pharmacokinetic parameters show that the absorption of TMP from the alimentary tract in pigs is faster than the absorption of SDZ, and the elimination of TMP is slower than that of SDZ."( A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs.
Garwacki, S; Grys, S; Lewicki, J; Rutkowski, J; Wiechetek, M; Zaremba, M, 1996
)
0.29
"Sulphamonomethoxine (SMM), sulphadimidine (SDD), sulphadiazine (SDZ) and their N4-acetyl derivatives (AcSMM, AcSDD and AcSDZ) were intravenously injected into Goettingen miniature pigs and deacetylation was evaluated from plasma concentration-time curves, renal excretion, and rate constants obtained from pharmacokinetic analysis, using a non-linear least-squares method."( Deacetylation as a determinant of sulphonamide pharmacokinetics in pigs.
Fujii, C; Okamoto, K; Shimoda, M; Sikazwe, G; Son, DS, 1997
)
0.3
"001/h and the half-life (t1/2beta) was 23."( Pharmacokinetics, bioavailability and dosage regimen of sulphadiazine (SDZ) in camels (Camelus dromedarius).
Kapoor, M; Kumar, R; Rai, AK; Singh, AP, 1998
)
0.3
" The influence of the drug combination on the intestinal microflora was examined and the plasma concentrations, pharmacokinetic parameters and plasma protein binding were determined."( Repeated administration of trimethoprim/sulfadiazine in the horse--pharmacokinetics, plasma protein binding and influence on the intestinal microflora.
Båverud, V; Franklin, A; Gunnarsson, A; Gustafsson, A; Ingvast-Larsson, C; Ogren, G, 1999
)
0.57
" The plasma concentrations of the drugs were determined by validated high-performance liquid chromatographic methods, and pharmacokinetic parameters were calculated."( Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens.
Baert, K; Croubels, S; De Backer, P; De Baere, S, 2003
)
0.58
" No differences in pharmacokinetic parameters were detected between the regimens."( Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients.
Alfaro, RM; Burstein, AH; Jordan, MK; Kovacs, JA; Pau, AK; Piscitelli, SC; Rock-Kress, D, 2004
)
0.62
" The half-life of the terminal phase (4."( Bioavailability and pharmacokinetics of sulphadiazine, N4-acetylsulphadiazine and trimethoprim following intravenous and intramuscular administration of a sulphadiazine/trimethoprim combination in sheep.
Batzias, GC; Delis, GA; Koutsoviti-Papadopoulou, M, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"A pharmacokinetic and bioavailability study of sulfadiazine combined with trimethoprim (sulfadiazine/trimethoprim) was carried out in fifteen healthy young ostriches after intravenous (i."( Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus).
Abu-Basha, EA; Al-Shunnaq, AF; Gehring, R; Hantash, TM; Idkaidek, NM, 2009
)
0.88
"A pharmacokinetic and tissue residue study of sulfadiazine combined with trimethoprim (SDZ/TMP = 5/1) was conducted in Siniperca chuatsi after single- (120 mg/kg) or multiple-dose (an initial dose of 120 mg/kg followed by a 5-day consecutive dose of 60 mg/kg) oral administrations at 28 °C."( A pharmacokinetic and residual study of sulfadiazine/trimethoprim in mandarin fish (Siniperca chuatsi) with single- and multiple-dose oral administrations.
Deng, Y; Jiang, L; Luo, L; Tan, A; Wang, W; Xiao, H; Zhang, R, 2016
)
0.96
" Pretreatment with allicin changed the pharmacokinetic behavior of orally administered sulfadiazine, by increasing AUC (41."( Allicin affects the pharmacokinetics of sulfadiazine and florfenicol by downregulating the expression of jejunum P-gp and BCRP in broilers.
Fang, C; Gong, Q; Huang, J; Wang, L; Wang, X; Wang, Y; Zhang, Y, 2022
)
1.21
" Therefore, the present study aimed to investigate pharmacokinetically the usefulness of the oral route in cattle by comparing the oral pharmacokinetic properties of two sulfonamides with different physicochemical properties."( Oral pharmacokinetics of sulfadiazine and sulfamonomethoxine in female Holstein milking cows.
Abugomaa, A; Elbadawy, M; Miura, R; Saiga, M; Sasaki, K; Shimoda, M; Tajima, T; Usui, T; Yamamoto, H, 2023
)
1.21

Compound-Compound Interactions

The activity of atovaquone in the treatment of murine toxoplasmosis was greatly enhanced when administered in combination with pyrimethamine or sulfadiazine. The 10-day treatment with 10mg/kg/day of fluconazole combined with 40/1mg/ kg/day sulfamethoxacin resulted in 93% survival of CF1 mice.

ExcerptReferenceRelevance
"Trimethoprim, in combination with sulfadiazine or sulfamethoxazole was administered orally for 7 to 14 days to 84 dogs with urinary tract infections (UTI)."( Trimethoprim in combination with a sulfonamide for oral treatment of canine urinary tract infections.
Ling, GV; Ruby, AL, 1979
)
0.54
" On the basis of literature data six sulphonamides, sulphadiazine, sulphachloropyridazine, sulphamethoxazole, sulphaisodimidine, sulphamerazine and sulphamethomidine appeared particularly suitable for combination with trimethoprim."( Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part I: Comparison of the antibacterial effect of sulphonamides alone and in combination with trimethoprim.
Bergan, T; Ekström, B; Forsgren, U; Ortengren, B, 1979
)
0.26
"The activity of the macrolide antibiotic clarithromycin was examined alone or in combination with other drugs for the treatment of acute or chronic infections with Toxoplasma gondii in mice."( Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis.
Araujo, FG; Lin, T; Prokocimer, P; Remington, JS, 1992
)
0.28
" Sulfamoxole (SMO), Sulfadiazine (SDZ) and Sulfadimidine (SDD) in combination with trimethoprim (TMP) were studied in 12 healthy volunteers."( Comparative pharmacokinetic study of four different sulfonamides in combination with trimethoprim in human volunteers.
Garg, SK; Ghosh, SS; Mathur, VS, 1986
)
0.59
" In this study, trimethoprim combined with sulphadiazine in the ratio 1:4 was compared when combined with sulphamethoxazole in the ratio 1:20."( Susceptibility testing to trimethoprim alone and combined with sulphonamides.
Dornbusch, K; Gezelius, L, 1980
)
0.26
"The efficacy of roxithromycin alone or in combination with pyrimethamine or sulphadiazine was examined in vitro and in a murine model of acute toxoplasmosis."( In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
Bryskier, A; Derouin, F; Moutot, M; Romand, S, 1995
)
0.29
"Sulfadiazine and the metabolites N4-acetyl-sulfadiazine, 4-OH-sulfadiazine, 5-OH-sulfadiazine, 5-OH-glucuronide-sulfadiazine, and 5-OH-sulfate-sulfadiazine were tested separately and in combination with pyrimethamine for the inhibitory activity on Toxoplasma gondii growth in vitro."( In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on Toxoplasma gondii.
Camps, W; Galama, J; Melchers, W; Schoondermark-van de Ven, E; Vree, T, 1995
)
2.06
"The efficacy of atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, and minocycline was examined in vitro and in a murine model of acute toxoplasmosis."( In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Derouin, F; Pudney, M; Romand, S, 1993
)
0.74
"The activity of atovaquone in the treatment of murine toxoplasmosis was greatly enhanced when administered in combination with pyrimethamine or sulfadiazine."( The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo, FG; Lin, T; Remington, JS, 1993
)
0.69
" Doses of each drug that were not effective in reducing inflammation in the brain of mice with toxoplasmic encephalitis when used alone were used in combination with a dose of rifabutin which was minimally effective."( Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo, FG; Remington, JS; Suzuki, Y, 1996
)
0.52
" The same dose protected 100% of infected mice when administered in combination with non-protective doses of atovaquone, clindamycin or sulphadiazine."( Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Araujo, FG; Bryskier, A; Khan, AA; Remington, JS, 1998
)
0.3
"The activity of recombinant bactericidal/permeability-increasing protein (rBPI21), alone or in combination with sulfadiazine, on the intracellular replication of Toxoplasma gondii was assessed in vitro and in mice with acute toxoplasmosis."( Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
Araujo, FG; Khan, AA; Lambert, LH; Remington, JS, 1999
)
0.74
" Amphotericin B was combined with flucytosine and ciprofloxacin, whereas itraconazole was combined with ciprofloxacin, levofloxacin, lomefloxacin and sulfadiazine."( In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera.
Afeltra, J; de Hoog, GS; Rijs, AJ; Verweij, PE; Vitale, RG, 2003
)
0.74
" The minor metabolite was characterized to some degree using H/D exchange and tandem mass spectrometry in combination with a high-resolution time of flight mass spectrometer."( Structural characterization of sulfadiazine metabolites using H/D exchange combined with various MS/MS experiments.
Fuchs, R; Pfeifer, T; Tuerk, J, 2005
)
0.61
"The compound 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone (PHNQ6) was evaluated for activity against Toxoplasma gondii, alone or combined with sulfadiazine."( Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.
Ferreira, RA; Oliveira, AB; Ribeiro, MF; Tafuri, WL; Vitor, RW, 2006
)
0.73
" Mechanisms through which polypharmacy may increase adverse health outcomes include decreased adherence, increased drug side effects, higher use of potentially inappropriate medications, and more frequent drug-drug interactions."( Appropriate prescribing and important drug interactions in older adults.
Paauw, DS; Wallace, J, 2015
)
0.42
"The aim of this study is to evaluate the effects of pyrimethamine (PYR) and sulfadiazine (SDZ) combined with levamisole and echinacea on the survival of mice infected with Toxoplasma gondii."( In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators.
Bilgin, K; Hokelek, M; Köksal, ZŞ; Yanik, K; Yılmaz, EM, 2016
)
0.66
" The purpose of this study was to determine the physicochemical stability of trimethoprim combined with sulfadiazine in PCCA base SuspendIt."( Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt.
Bostanian, LA; Graves, RA; Mandal, TK; Phan, KV; Pramar, YV,
)
0.57
"In this study, the effects of the treatment with different doses of fluconazole (FLZ) in combination with the current treatment of acute toxoplasmosis on reducing the mortality rate and the parasitic load in the murine model in vivo were studied."( Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.
Anita, M; Hadi, M; Mohammad, JM; Reza, S; Sina, S; Soudabeh, E, 2021
)
0.82

Bioavailability

The mean oral bioavailability of sulfadiazine was high. The extent and rate of absorption for trimethoprim were variable, but peak serum concentrations occurred generally within 3 hours. The absorption rate constant of each sulfonamide increased with increase in temperature.

ExcerptReferenceRelevance
" This new dissolution tester possibly can be useful in determining drug release from solid dosage forms and correlating it with in vivo bioavailability because dissolution rate can be controlled easily with the adjustment of air pressure without complicated changes in the apparatus, there is no excessive settling of particles, and complete drug dissolution can be achieved with no clogging of the screen."( New in vitro dissolution test apparatus.
Nasir, SM; Nasir, SS; Wilken, LO, 1979
)
0.26
"The bioavailability of seven commercial trisulfapyrimidine suspensions was studied in 14 adult male volunteers."( Bioavailability and dissolution behavior of trisulfapyrimidine suspensions.
Barry, H; Colaizzi, JL; Goehl, TJ; Jaffe, JM; Mathur, LK; Poust, RI; Shah, VP, 1979
)
0.26
"A four-way crossover sulfadiazine bioavailability study was conducted in 16 normal healthy male volunteers."( Bioavailability of sulfadiazine solutions, suspensions, and tablets in humans.
Biola Mabadeje, AF; Cavagnol, JC; Meyer, MC; Ramachander, G; Straughn, AB, 1978
)
0.91
" The findings show that reliance on plasma concentration curves alone in determinations of bioavailability of chemotherapeutic agents may lead to false interpretations."( Distribution of trimethoprim/sulphadiazine in plasma, tissue and synovial fluids.
Piercy, DW, 1978
)
0.26
" With the commercial tablet as a standard, the extent of bioavailability was determined in rabbits; it was slightly higher for both the direct compression and fluidized-bed tablets."( Bioavailability of sulfadiazine in rabbits using tablets prepared by direct compression and fluidized-bed granulation.
Erni, W; Ritschel, WA, 1977
)
0.59
" Transdermal delivery of a combined preparation of TMP/SDZ may be usable for colibacillosis of sucking piglets, although the bioavailability of the drugs is poor."( Transdermal delivery and intramuscular injection of trimethoprim/sulphadiazine in sucking piglets.
Hayama, T; Kokue, E; Sekido, T; Shimoda, M, 1992
)
0.28
" The in vitro dissolution and in vivo bioavailability of two commercial trimethoprim-sulfadiazine-sulfamethoxazole tablets (A and B) were studied."( [Studies on the dissolution and bioavailability of trimethoprim-sulfadiazine-sulfamethoxazole tablets].
Mao, FF; Shao, J; Tu, XD, 1992
)
0.75
"The dissolution procedure serves as a quality control test to assure batch-to-batch uniformity and bioequivalence of a product once the bioavailability of the product has been established."( Influence of higher rates of agitation on release patterns of immediate-release drug products.
Dighe, S; Gurbarg, M; Noory, A; Shah, VP; Skelly, JP, 1992
)
0.28
"The paper describes a comparative bioavailability study on two tablet formulations containing 100 mg of tetroxoprim and 250 mg of sulphadiazine."( Bioequivalency studies on tablet formulation of tetroxoprim and sulphadiazine.
Alkaysi, HN; Badwan, AA; Gharaibeh, AM; Gharaibeh, KI; Salem, MA, 1992
)
0.28
" Bioavailability after oral administration was approximately 100% of sulphadiazine, but only about 60% for TMP."( Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers.
Fassbender, CP; Kietzmann, M; Löscher, W; Weissing, M, 1990
)
0.28
" Comparative bioavailability calculations showed no statistically significant differences between sulphadiazine and trimethoprim in the three preparations."( A comparison of some of the pharmacokinetic parameters of three commercial sulphadiazine/trimethoprim combined preparations given orally to pigs.
Framstad, T; Odegaard, SA; Skjerve, E; Sohlberg, S; Søli, NE, 1990
)
0.28
" Tetroxoprim embonate, an insoluble salt very useful for obtaining a suspension with good palatability, shows a bioavailability not statistically different from that of tetroxoprim base."( HPLC determination of tetroxoprim and sulphadiazine in pharmaceutical dosage forms and in biological fluids.
Coppi, G; Springolo, V, 1989
)
0.28
" Trimethoprim bioavailability, following oral administration at 1, 6 and 12 weeks of age, is higher in milk-fed calves (non-ruminants) than in grain-fiber-fed calves (ruminants); bioavailability decreases with increasing age in both groups of calves."( The effect of age and diet on sulfadiazine/trimethoprim disposition following oral and subcutaneous administration to calves.
Guard, CL; Schwark, WS; Shoaf, SE, 1987
)
0.56
" The most important conclusion was that amoxycillin, chloramphenicol, and trimethoprim were suitable for oral administration to veal calves, although the bioavailability of chloramphenicol and trimethoprim was significantly less when concurrently administered with a milk replacer."( Salmonellosis in veal calves. Some therapeutic aspects.
Groothuis, DG; van Miert, AS, 1987
)
0.27
" The most important conclusion was that amoxycillin, chloramphenicol, and trimethoprim were suitable for oral administration to vealcalves, although the bioavailability of chloramphenicol and trimethoprim was significantly less when administered with a milk replacer concurrently."( [Therapeutic aspects of salmonellosis in veal calves].
Groothuis, DG; van Miert, AS, 1985
)
0.27
" In dogs with healthy meninges, the CSF bioavailability - expressed as the ratio of CSF/plasma area under the curve 0-5-hour values - following continuous infusion was determined to be 86."( Diffusion of metioprim, tetroxoprim and sulphadiazine in the cerebrospinal fluid of dogs with healthy meninges and dogs with experimental meningitis.
Armengaud, H; Bishop-Freudling, GB; Foing, N; Szelenyi, I; van Tho, T; Vergin, H, 1984
)
0.27
" The net result was that the comparative bioavailability of the drug was higher in PEM as compared to the control."( Disposition of four drugs in malnourished children.
Mathur, VS; Mehta, S; Nain, CK; Sharma, B, 1982
)
0.26
" The extent and rate of absorption for trimethoprim were variable, but peak serum concentrations occurred generally within 3 hours; sulfadiazine absorption was slower, reaching peak concentrations by 6 hours."( Serum concentrations of trimethoprim and sulfadiazine following oral paste administration to the horse.
Byars, TD; DeAngelis, D; Divers, TJ; Murch, O; Sigel, CW, 1981
)
0.73
" Based on bioavailability and the resulting plasma concentrations it is concluded that the oral administration of SDZ and TMP was efficient in both the fed and fasted pigs."( Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs.
Gyrd-Hansen, N; Nielsen, P, 1994
)
0.29
" The absorption rate constant (Kab) of each sulfonamide increased with increase in temperature and, at each temperature, Kab was the highest for sulfamethazine and the lowest for sulfadiazine."( Elucidation of the role of hydrophobic bonding in influencing intestinal absorption of model sulfonamides and revealing possible mechanism of drug absorption in rat model.
Chow, SL; Nagwekar, JB, 1993
)
0.48
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" While atovaquone has potent in vitro activity against Toxoplasma gondii, it is poorly absorbed after oral administration and shows poor therapeutic efficacy against TE."( Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Borner, K; Hahn, H; Kayser, O; Krause, K; Liesenfeld, O; Müller, RH; Schöler, N, 2001
)
0.31
" The oral bioavailability was approximately 80% for both components."( Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens.
Baert, K; Croubels, S; De Backer, P; De Baere, S, 2003
)
0.58
" Sulphadiazine bioavailability (+/-SD) was 69."( Bioavailability and pharmacokinetics of sulphadiazine, N4-acetylsulphadiazine and trimethoprim following intravenous and intramuscular administration of a sulphadiazine/trimethoprim combination in sheep.
Batzias, GC; Delis, GA; Koutsoviti-Papadopoulou, M, 2005
)
0.33
" The effects were visible for up to 4 days after application of the manure with or without SDZ and were correlated with the bioavailability of the antibiotic."( Alterations in soil microbial activity and N-transformation processes due to sulfadiazine loads in pig-manure.
Heuer, H; Kotzerke, A; Schauss, K; Schloter, M; Sharma, S; Smalla, K; Thiele-Bruhn, S; Wilke, BM, 2008
)
0.57
"A pharmacokinetic and bioavailability study of sulfadiazine combined with trimethoprim (sulfadiazine/trimethoprim) was carried out in fifteen healthy young ostriches after intravenous (i."( Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus).
Abu-Basha, EA; Al-Shunnaq, AF; Gehring, R; Hantash, TM; Idkaidek, NM, 2009
)
0.88
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Bioavailability was 74% for SDZ and 46% for TMP after paste administration in fed horses."( Antimicrobial disposition in pulmonary epithelial lining fluid of horses. Part I. Sulfadiazine and trimethoprim.
Baptiste, KE; Friis, C; Guardabassi, L; Winther, L, 2011
)
0.59
" Water absorption rate constants (mg/cm(2)/min(0."( Physicochemical properties of macrogol ointment and emulsion ointment blend developed for regulation of water absorption.
Fujii, S; Noda, Y; Sanagawa, A; Sobajima, Y; Watanabe, K, 2011
)
0.37
"Understanding the long-term sequestration of veterinary antibiotics into soil fractions with different bioavailability is important in terms of assessing their eco-toxicological impact."( Long-term sorption and sequestration dynamics of the antibiotic sulfadiazine: a batch study.
Groeneweg, J; Kasteel, R; Sittig, S; Vereecken, H,
)
0.37
" In future, this method may be used as a tool for the assessment of bioavailability of antibiotics in soil."( Plasmid-mediated fitness advantage of Acinetobacter baylyi in sulfadiazine-polluted soil.
Heuer, H; Jechalke, S; Kopmann, C; Moenickes, S; Richter, M; Smalla, K, 2013
)
0.63
" The mean oral bioavailability of sulfadiazine was high (83."( Oral absorption profiles of sulfonamides in Shiba goats: a comparison among sulfadimidine, sulfadiazine and sulfanilamide.
Aboubakr, M; Elbadawy, M; Ishihara, Y; Sasaki, K; Shimoda, M, 2016
)
0.93
"The poor oral bioavailability of tetracyclines resulted in rather high concentrations in cecal and colonic content and feces at steady-state conditions."( Residues of chlortetracycline, doxycycline and sulfadiazine-trimethoprim in intestinal content and feces of pigs due to cross-contamination of feed.
Butaye, P; Croubels, S; Daeseleire, E; Devreese, M; Dewulf, J; Haesebrouck, F; Heyndrickx, M; Imberechts, H; Peeters, LE; Rasschaert, G; Smet, A, 2016
)
0.69
"The relation between the oral bioavailability and intestinal concentrations of the tested antimicrobials, may be of help in assessing the risks of cross-contaminated feed."( Residues of chlortetracycline, doxycycline and sulfadiazine-trimethoprim in intestinal content and feces of pigs due to cross-contamination of feed.
Butaye, P; Croubels, S; Daeseleire, E; Devreese, M; Dewulf, J; Haesebrouck, F; Heyndrickx, M; Imberechts, H; Peeters, LE; Rasschaert, G; Smet, A, 2016
)
0.69
" The high oral bioavailability of SDZ indicates gastrointestinal secretion is a substantial elimination route for SDZ."( Effect of administration route and dose alteration on sulfadiazine-trimethoprim plasma and intestinal concentrations in pigs.
Croubels, S; De Backer, P; De Smet, J; Devreese, M, 2017
)
0.7
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" SDBS was effectively to disintegrate the cemented structure of extracellular polymeric substances and meanwhile improve the SDZ solubilization, which increase the SDZ bioavailability as well as biotoxicity to the anaerobic species."( Surfactant and antibiotic co-occurrence reshaped the acidogenic process for volatile fatty acids production during sludge anaerobic fermentation.
Cheng, X; Fang, S; Huang, W; Liu, J; Liu, X; Luo, J; Wang, F; Wei, Z; Wu, J; Wu, Y; Zhang, L, 2023
)
0.91

Dosage Studied

Six healthy adult mixed breed dogs were each given 5 oral doses of trimethoprim (TMP)/sulfadiazine (SDZ) at 2 dosage regimens: 5 mg of TMP/kg of body weight and 25 mg of SDZ/kg every 24 hours. Based on this study, an optimal dosage regimen of sulfad Diazine in buffalo calves would be 165 mg/kg, followed by 75mg/kg at 12-h intervals.

ExcerptRelevanceReference
"The four parameter equation, applicable to drug absorption kinetics over a limited time period, has been used to interpret plasma concentration, time results following oral dosage with three different formulations of sulphadiazine tablets, to each of five subjects."( A model for short term drug absorption studies; comparison of sulphadiazine tablets.
Ahmed, M; Enever, RP; Natunen, T; Saunders, L, 1978
)
0.26
" The daily dosage of 26."( Trimethoprim in combination with a sulfonamide for oral treatment of canine urinary tract infections.
Ling, GV; Ruby, AL, 1979
)
0.26
" Co-trimazine was found to have a greater antibacterial activity than co-trimoxazole and its use at a lower dosage than that of the latter appears warranted."( Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat.
Ritzerfeld, W, 1979
)
0.26
"The effects of a twice daily dosage of a combination of 410 mg sulphadiazine + 90 mg trimethoprim (SD + TMP) and 800 mg sulphamethoxazole + 160 mg trimethoprim (SMZ + TMP) were compared in uncomplicated urinary tract infections."( Double-blind comparison of sulphonamide-trimethoprim combinations in acute uncomplicated urinary tract infections.
Bergan, T; Skjerven, O, 1979
)
0.26
" This new dissolution tester possibly can be useful in determining drug release from solid dosage forms and correlating it with in vivo bioavailability because dissolution rate can be controlled easily with the adjustment of air pressure without complicated changes in the apparatus, there is no excessive settling of particles, and complete drug dissolution can be achieved with no clogging of the screen."( New in vitro dissolution test apparatus.
Nasir, SM; Nasir, SS; Wilken, LO, 1979
)
0.26
"There are many difficulties in creating a simple and useful dosage schedule for co-trimazine treatment in children."( Studies on the optimal dosage of co-trimazine in children.
Bergfors, PG, 1979
)
0.26
" With the former drug, the result of scrutiny for crystals after dosage until the steady state was negative, whereas crystals of acetylated sulphamethoxazole were detected and verified chemically in two of eight subjects."( Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 3: Pharmacokinetic characterization of sulphadiazine and sulphamethoxazole given with trimethoprim.
Bergan, T; Magni, L; Ortengren, B, 1979
)
0.26
" On the basis of the pharmacokinetic properties, dosage schedules are suggested that will give approximately the same plasma levels regardless of renal function."( Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function.
Anstad, U; Bergan, T; Brodwall, EK; Vik-Mo, H, 1979
)
0.26
" Each group received four different oral dosage forms of sulfadiazine at 1-week intervals: a solution as a reference, a suspension, and two different tablets."( Bioavailability of sulfadiazine solutions, suspensions, and tablets in humans.
Biola Mabadeje, AF; Cavagnol, JC; Meyer, MC; Ramachander, G; Straughn, AB, 1978
)
0.83
" After oral dosing there was good gastrointestinal absorption of both antibacterial agents in dogs but only of the sulphonamide in sheep."( Distribution of trimethoprim/sulphadiazine in plasma, tissue and synovial fluids.
Piercy, DW, 1978
)
0.26
" It is concluded that a revision in the dosage schedule may not be necessary in the treatment of under-nourished subjects with sulphadiazine, since the blood concentrations were higher than the reporte d minimum to combat infection."( Metabolism of sulphadiazine in malnutrition.
Arunkumar Shastri, R; Krishnaswamy, K, 1979
)
0.26
"Serum level studies in cats and dogs dosed with 30 mg per kg per day of either oral or injectable formulations of a 1:5 trimethoprim/sulphadiazine combination showed good absorption by both routes of administration."( Studies in dogs and cats dosed with trimethoprim and sulphadiazine.
Craig, GR; White, G, 1976
)
0.26
"18 for the 50-mg/day and 25-mg/day dosage of pyrimethamine, respectively."( Ocular toxoplasmosis in human immunodeficiency virus-infected patients.
Cochereau-Massin, I; Girard, B; Katlama, C; Lautier-Frau, M; LeHoang, P; Leport, C; Marcel, P; Robinet, M; Zazoun, L; Zerdoun, E, 1992
)
0.28
" Based on this study, an optimal dosage regimen of sulfadiazine in buffalo calves would be 165 mg/kg, followed by 75 mg/kg at 12-h intervals."( Pharmacokinetics and urinary excretion of sulfadiazine in buffalo calves.
Garg, BD; Jain, SK; Uppal, RP, 1992
)
0.8
"Six healthy adult mixed breed dogs were each given 5 oral doses of trimethoprim (TMP)/sulfadiazine (SDZ) at 2 dosage regimens: 5 mg of TMP/kg of body weight and 25 mg of SDZ/kg every 24 hours (experiment 1) and every 12 hours (experiment 2)."( Serum and skin concentrations after multiple-dose oral administration of trimethoprim-sulfadiazine in dogs.
Brown, MP; Gronwall, R; Kunkle, GA; Merritt, K; Pohlenz-Zertuche, HO, 1992
)
0.73
" Dosage must be adjusted to the results of blood counts."( [Usefulness of folinic acid in cytopenia induced by antiparasitic drugs in AIDS patients].
Leport, C; Niyongabo, T; Vildé, JL, 1991
)
0.28
" Oral dosing of TMP in combination with sulphadimidine yielded similar maximum plasma concentrations of both compounds to those obtained with the combination of TMP with sulphadiazine, but the plasma concentration decline of sulphadimidine appeared to be more rapid than that of sulphadiazine after oral administration."( Drug plasma levels following administration of trimethoprim and sulphonamide combinations to broilers.
Fassbender, CP; Kietzmann, M; Löscher, W; Weissing, M, 1990
)
0.28
" A satisfactory intravenous dosage regimen of sulfadiadine in the treatment of infections in calves would be 125 mg/kg, followed by 100 mg/kg at 24 h intervals."( Disposition kinetics and dosage regimen of sulfadiadine in crossbred calves.
Chaudhary, RK; Raina, R; Srivastava, AK, 1990
)
0.28
"Two HPLC methods for determination of tetroxoprim and sulphadiazine in pharmaceutical dosage forms and in biological fluid are reported."( HPLC determination of tetroxoprim and sulphadiazine in pharmaceutical dosage forms and in biological fluids.
Coppi, G; Springolo, V, 1989
)
0.28
" Administration of the TMP-SDZ combination at a dosage of 30 mg/kg once daily was not effective in maintaining TMP or SDZ concentrations above the MIC of TMP-SDZ for the S aureus (0."( Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis.
Bertone, AL; Jones, RL; McIlwraith, CW, 1988
)
0.51
"The present investigation was undertaken to improve regimens dosage of amoxycillin, chloramphenicol or trimethoprim-sulphadiazine in Salmonella dublin infected veal calves."( Salmonellosis in veal calves. Some therapeutic aspects.
Groothuis, DG; van Miert, AS, 1987
)
0.27
" The dosage and the duration of the therapy must be adapted to each case."( [Efficacy of specific chemotherapy in the prevention of recurrences of toxoplasmic chorioretinitis during the 4 years following the treatment].
Bloch-Michel, E; Timsit, JC, 1987
)
0.27
" The data indicate that, while therapeutic concentrations and optimum ratios of the drugs may be achieved for extended time periods in neonatal life, this dosage is unable to produce optimum serum and synovial fluid concentrations as the calves mature."( Age-related alterations in trimethoprim-sulfadiazine disposition following oral or parenteral administration in calves.
Blackshear, P; Friedman, DS; Guard, CL; Haluska, M; Schwark, WS, 1986
)
0.54
" Starting 2 days after infection was induced, group-II dogs were treated with trimethoprim-sulfadiazine at a dosage of 15 mg/kg given orally 2 times a day for 21 days; groups-III and -IV dogs were treated with single oral dosages of the antibiotic at 60 mg/kg and 90 mg/kg, respectively."( Comparison of single-dose and conventional trimethoprim-sulfadiazine therapy in experimental Staphylococcus intermedius cystitis in the female dog.
Cox, HU; Gossett, KA; Kearney, MT; Roy, AF; Thomas, DE; Troy, GC; Turnwald, GH, 1986
)
0.74
"The present investigation was undertaken to improve dosage regimens--using amoxycillin, chloramphenicol or trimethoprim/sulphadiazin--in Salmonella dublin or Salmonella typhimurium infected vealcalves."( [Therapeutic aspects of salmonellosis in veal calves].
Groothuis, DG; van Miert, AS, 1985
)
0.27
" They suffered from acute urinary tract infection and were treated with conventional dosage regimen of either of the sulfonamides."( Sulfadiazine versus sulfafurazole excretion in urine and risk of crystallization in children with conventional dosage regimen.
Anttila, R; Janas, M; Wilén, G; Ylitalo, P, 1985
)
1.71
" To overcome this degree of resistance it is necessary to give a soluble penicillin preparation intramuscularly in very high dosage (2-8 million units)."( Development of resistance of gonococci to penicillin: an eight-year study.
Amies, CR, 1967
)
0.25
" Used in high dosage by the intraventricular as well as the intravenous route, this drug might be successful in the treatment of further cases of primary amoebic meningoencephalitis."( Sensitivity to amphotericin B of a Naegleria sp. isolated from a case of primary amoebic meningoencephalitis.
Carter, RF, 1969
)
0.25
" The treatment lasted for 14 days but was extended up to 42 days in cases involving a risk of reinfection (indwelling catheter) or obvious chronicity of the complaint; and in some cases the therapy was continued at a reduced dosage of one half tablet once daily."( [Chemotherapy of urinary tract infections and of respiratory diseases with tibirox in a long-termin hospital (author's transl)].
Ludwig, KG, 1982
)
0.26
" In their concluding remarks the authors state that in addition to being effective in the morbid condition selected for trial, cotrimazine offers some advantages over similar combinations of TMP and other sulfonamides, both because of the intrinsic physicochemical and pharmacological properties of SDZ and because of its lower dosage in this combination."( A clinical trial of co-trimazine (sulfadiazine + trimethoprim) in flare-ups of chronic bronchitis.
Lanza, R; Leone, G; Paoletti, V; Parlapiano, C; Vincentelli, GM, 1984
)
0.55
"Two studies were conducted in neurosurgical patients to establish cerebrospinal fluid (CSF) and plasma levels of tetroxoprim (TXP) and sulphadiazine (SDZ) following the oral administration of co-tetroxazin in a standard dosage regimen."( [Diffusion of tetroxoprim and sulfadiazine in the cerebrospinal fluid of neurosurgery patients].
Albert, F; Bishop-Freudling, GB; Vergin, H, 1984
)
0.56
" During the dosage interval of 24 h, sulphadiazine and trimethoprim concentrations exceeded the MIC values of the common respiratory pathogens in serum and secretion."( Concentrations of sulphadiazine and trimethoprim in nasal secretion after co-trimazine administration.
Bamberg, P; Giebel, W; Ullmann, U, 1983
)
0.27
"A double-blind trial was carried out in 177 patients with acute symptomatic urinary tract infections to assess the efficacy and tolerability of nitrofurantoin plus sulphadiazine at two dosage levels."( Double-blind clinical trial of a nitrofurantoin/sulphadiazine combination at two dosage levels in acute symptomatic urinary infections.
Morris, RW; Reeves, DS; Reeves, RE; Watts, MR, 1980
)
0.26
" Although the amount of SD was only about 1/3 of that of SM it seems to be a comparable alternative with this small dosage in combination with TMP, when bacterial infections in the urinary tract or in the male reproductive organs are treated."( The penetration of sulfadiazine, sulfamethoxazole and trimethoprim into the prostate gland, epididymis and testis in man.
Seppänen, J, 1980
)
0.59
"Two fasted and 2 fed horses were dosed orally with a combined trimethoprim and sulfadiazine paste formulation at a dose of 35 mg (1:5 combined active ingredients)/kg."( Serum concentrations of trimethoprim and sulfadiazine following oral paste administration to the horse.
Byars, TD; DeAngelis, D; Divers, TJ; Murch, O; Sigel, CW, 1981
)
0.76
" SD in lower than the usual dosage would appear to be a practical alternative in the treatment of acute urinary tract infections caused by sulfonamide-sensitive micro-organisms in children."( Reduced sulfadiazine dose in the treatment of acute urinary tract infection in children.
Anttila, R; Julkunen, R; Seppänen, J, 1980
)
0.7
" The metabolism of [14C]benzoate and of p-aminobenzoic acid in the neonatal marmoset was compared with that in similarly dosed neonatal rats."( Some pathways of xenobiotic metabolism in the adult and neonatal marmoset (Callithrix jacchus).
Hall, BE; James, SP, 1980
)
0.26
" Sows in five of the groups were dosed with high levels of tiamulin and trimethoprim-sulphonamide preparations from their entry into the farrowing house until their biggest piglets were weaned."( Medicated early weaning to obtain pigs free from pathogens endemic in the herd of origin.
Alexander, TJ; Boon, G; Gush, AF; Lysons, RJ; Thornton, K, 1980
)
0.26
" The dosage regimen for pyrimethamine and sulfadiazine was established by pharmacokinetic studies in two monkeys."( Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.
Baars, I; Camps, W; Eskes, T; Galama, J; Melchers, W; Meuwissen, J; Schoondermark-van de Ven, E; Vree, T, 1995
)
0.77
"Derivative and difference spectrophotometric methods are described for the direct simultaneous analysis of combinations of Trimethoprim with sulfonamide drugs (sulfadiazine, sulfamethoxazole, sulfamethoxypyridazine) in commercial dosage forms."( Analysis of Trimethoprim--sulfonamide drug combinations in dosage forms by UV spectroscopy and liquid chromatography (HPLC).
Andrisano, V; Bonazzi, D; Cavrini, V; Di Pietra, AM, 1994
)
0.49
" This pilot study suggests that the combination of pyrimethamine and azithromycin may be further investigated and that the optimal dosage of azithromycin has yet to be determined."( Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS.
Hazebroucq, V; Joly, V; Leport, C; Morlat, P; Raffi, F; Saba, J; Vildé, JL, 1993
)
0.29
" All the cows were treated with 20 g sulphadiazine and 4 g trimethoprim intramuscularly upon diagnosis, and half the dosage was given once daily thereafter."( Anti-inflammatory ketoprofen in the treatment of field cases of bovine mastitis.
Chen, R; Longo, F; Saran, A; Shpigel, NY; Winkler, M; Ziv, G, 1994
)
0.29
" These results suggest that combining rifabutin with certain drugs that are active against Toxoplasma gondii may be useful for the treatment of toxoplasmic encephalitis in humans and may allow for a reduction in dosage of either or both drugs with a resulting reduction in untoward side effects."( Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo, FG; Remington, JS; Suzuki, Y, 1996
)
0.52
" upon diagnosis and half dosage once daily thereafter."( The anti-inflammatory drugs phenylbutazone and dipyrone in the treatment of field cases of bovine mastitis.
Saran, A; Shpigel, NY; Winkler, M; Ziv, G, 1996
)
0.29
" These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis."( Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients.
Alfaro, RM; Burstein, AH; Jordan, MK; Kovacs, JA; Pau, AK; Piscitelli, SC; Rock-Kress, D, 2004
)
0.86
" annua infusion before infection in HFF cells showed a dose-response inhibitory curve that reached up to 75% of inhibition, similarly to the results observed when parasites were treated with sulfadiazine."( Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo.
Béla, SR; de Oliveira, TC; Ferro, EA; Magalhães, PM; Mineo, JR; Rostkowska, C; Silva, DA, 2009
)
0.54
" Sulfamethoxazole and trimethoprim show good dose-response relationships."( [Effects of antimicrobial drugs on soil microbial respiration].
Li, X; Liu, F; Su, HC; Tao, R; Ying, GG; Zhou, QX, 2009
)
0.35
" The influence of three frequently used antibiotics, copper dosed as CuSO(4), sulfadiazine (SDZ), and difloxacin (DIF), on the anaerobic digestion process of pig manure was studied in semi-continuous experiments."( Short term effects of copper, sulfadiazine and difloxacin on the anaerobic digestion of pig manure at low organic loading rates.
Clemens, J; Dong, R; Guo, J; Ostermann, A; Siemens, J, 2012
)
0.9
"Horses with lower respiratory tract infections caused by S equi subsp zooepidemicus were treated with a new formulation of combined trimethoprim-sulfadiazine oral suspension at a dosage of 24 mg/kg (10."( A randomized controlled field trial of a novel trimethoprim-sulfadiazine oral suspension for treatment of Streptococcus equi subsp zooepidemicus infection of the lower respiratory tract in horses.
Hawkins, PA; Koenig, R; McClure, SR, 2015
)
0.86
" In most cases, it was not severe and reversed after increase in folinic acid dosage (25."( High Frequency of Bone Marrow Depression During Congenital Toxoplasmosis Therapy in a Cohort of Children Identified by Neonatal Screening in Minas Gerais, Brazil.
Carellos, EVM; de Andrade, GMQ; de Andrade, JQ; Figueiredo, RM; Januário, JN; Romanelli, RMC; Tibúrcio, JD; Vasconcelos-Santos, DV, 2017
)
0.46
" Conventional dosing (30 mg SDZ-TRIM/kg bodyweight [BW]) and half dosing (15 mg SDZ-TRIM/kg BW) was performed for the oral routes in two applications per day."( Effect of administration route and dose alteration on sulfadiazine-trimethoprim plasma and intestinal concentrations in pigs.
Croubels, S; De Backer, P; De Smet, J; Devreese, M, 2017
)
0.7
" There are no published studies of the stability of the combination of trimethoprim and sulfadiazine in a liquid dosage form."( Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt.
Bostanian, LA; Graves, RA; Mandal, TK; Phan, KV; Pramar, YV,
)
0.57
"The sulfadiazine suspension in simple syrup was chosen as the most suitable formulation because it demonstrated stability for 14 days at room temperature, providing an alternative liquid dosage form of sulfadiazine for congenital toxoplasmosis treatment."( Stability of extemporaneous sulfadiazine oral suspensions from commercially available tablets for treatment of congenital toxoplasmosis.
Barreto Gomes, AP; Mafra Veríssimo, L; Pontes do Nascimento, L; Soares Rodrigues Costa, B; Vítor de Paiva Amorim, M, 2020
)
1.41
" The aims of this study were to assess, in a PKPD framework, the empirical dosage regimen for a combination of trimethoprim (TMP) and sulfadiazine (SDZ) in mink, and secondarily to produce data for future setting of clinical breakpoints."( Validating an empiric sulfadiazine-trimethoprim dosage regimen for treatment of Escherichia coli and Staphylococcus delphini infections in mink (Neovison vison).
Damborg, P; Frandsen, HL; Hansen, SG; Nikolaisen, NK; Poulsen, HH; Ronaghinia, AA; Struve, T; Toutain, PL, 2021
)
1.14
"015) despite an identical SA dosing scheme."( Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case-control study.
Enders, M; Garweg, JG; Gruetzmacher, B; Hlobil, H; Hoerauf, A; Klarmann-Schulz, U; Reiter-Owona, I; Rilling, V, 2020
)
2
"5 μg/ml using the studied dosing regimen."( The disposition of trimethoprim and sulfadiazine in neonatal foals after intravenous administration.
Bondesson, U; Bröjer, J; Ekstrand, C; Gehring, R; Nostell, K, 2022
)
1
" Two typical sulfonamides antibiotics (sulfamethoxazole, sulfadiazine) adsorption capacity were evaluated in terms of the dosage of composite materials, the ratio of each component, and the pH of the solution."( Preparation of β-cyclodextrin/dopamine hydrochloride-graphene oxide and its adsorption properties for sulfonamide antibiotics.
Deng, C; Ding, H; Liu, X; Xu, X; Yu, H; Yu, Z; Zhao, B; Zheng, K, 2022
)
0.97
" Infected mice were dosed with MQ solution or MQ-niosomes at 50 mg/kg/day, starting from the second day post-infection (PI) (acute model) or the fifth week PI (chronic model), and this was continued for six consecutive days."( Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis.
Aboul Asaad, IA; Amer, BS; Carter, WG; El Maghraby, GM; El Sharazly, BM; Ismail, HIH; Mohamed, DA; Yassen, NA, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (9)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
coccidiostatAn agent useful in the treatment or prevention of coccidiosis in man or animals.
antiprotozoal drugAny antimicrobial drug which is used to treat or prevent protozoal infections.
EC 2.5.1.15 (dihydropteroate synthase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitorAn EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the activity of sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming), EC 1.1.1.153, which plays an important part in the biosynthesis of tetrahydrobiopterin.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
substituted aniline
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency7.94330.01846.806014.1254AID624417
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency23.91850.01237.983543.2770AID1645841
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency11.22020.794321.275750.1187AID624246
gemininHomo sapiens (human)Potency35.48130.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency6.91110.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency0.17780.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aurora kinase AHomo sapiens (human)IC50 (µMol)21.00000.00000.46208.6000AID405525
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)422.66670.11007.190310.0000AID1443980; AID1449628; AID1473738
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)12.72030.00582.14107.9000AID1803142
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)12.72030.00021.10608.3000AID1803142
Carbonic anhydrase 6Homo sapiens (human)IC50 (µMol)12.72030.02001.33175.7900AID1803142
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (86)

Processvia Protein(s)Taxonomy
protein phosphorylationAurora kinase AHomo sapiens (human)
response to woundingAurora kinase AHomo sapiens (human)
liver regenerationAurora kinase AHomo sapiens (human)
G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
mitotic cell cycleAurora kinase AHomo sapiens (human)
chromatin remodelingAurora kinase AHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
apoptotic processAurora kinase AHomo sapiens (human)
spindle organizationAurora kinase AHomo sapiens (human)
spindle assembly involved in female meiosis IAurora kinase AHomo sapiens (human)
mitotic centrosome separationAurora kinase AHomo sapiens (human)
anterior/posterior axis specificationAurora kinase AHomo sapiens (human)
regulation of G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
negative regulation of gene expressionAurora kinase AHomo sapiens (human)
peptidyl-serine phosphorylationAurora kinase AHomo sapiens (human)
regulation of protein stabilityAurora kinase AHomo sapiens (human)
negative regulation of protein bindingAurora kinase AHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
negative regulation of apoptotic processAurora kinase AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
positive regulation of mitotic nuclear divisionAurora kinase AHomo sapiens (human)
positive regulation of mitotic cell cycleAurora kinase AHomo sapiens (human)
regulation of centrosome cycleAurora kinase AHomo sapiens (human)
protein autophosphorylationAurora kinase AHomo sapiens (human)
cell divisionAurora kinase AHomo sapiens (human)
centrosome localizationAurora kinase AHomo sapiens (human)
cilium disassemblyAurora kinase AHomo sapiens (human)
protein localization to centrosomeAurora kinase AHomo sapiens (human)
positive regulation of mitochondrial fissionAurora kinase AHomo sapiens (human)
positive regulation of oocyte maturationAurora kinase AHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase AHomo sapiens (human)
neuron projection extensionAurora kinase AHomo sapiens (human)
mitotic spindle organizationAurora kinase AHomo sapiens (human)
regulation of cytokinesisAurora kinase AHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
protein kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase AHomo sapiens (human)
protein bindingAurora kinase AHomo sapiens (human)
ATP bindingAurora kinase AHomo sapiens (human)
protein kinase bindingAurora kinase AHomo sapiens (human)
ubiquitin protein ligase bindingAurora kinase AHomo sapiens (human)
histone H3S10 kinase activityAurora kinase AHomo sapiens (human)
protein heterodimerization activityAurora kinase AHomo sapiens (human)
protein serine kinase activityAurora kinase AHomo sapiens (human)
molecular function activator activityAurora kinase AHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (45)

Processvia Protein(s)Taxonomy
spindle microtubuleAurora kinase AHomo sapiens (human)
nucleusAurora kinase AHomo sapiens (human)
nucleoplasmAurora kinase AHomo sapiens (human)
centrosomeAurora kinase AHomo sapiens (human)
centrioleAurora kinase AHomo sapiens (human)
spindleAurora kinase AHomo sapiens (human)
cytosolAurora kinase AHomo sapiens (human)
postsynaptic densityAurora kinase AHomo sapiens (human)
microtubule cytoskeletonAurora kinase AHomo sapiens (human)
basolateral plasma membraneAurora kinase AHomo sapiens (human)
midbodyAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
ciliary basal bodyAurora kinase AHomo sapiens (human)
germinal vesicleAurora kinase AHomo sapiens (human)
axon hillockAurora kinase AHomo sapiens (human)
pronucleusAurora kinase AHomo sapiens (human)
perinuclear region of cytoplasmAurora kinase AHomo sapiens (human)
mitotic spindleAurora kinase AHomo sapiens (human)
meiotic spindleAurora kinase AHomo sapiens (human)
mitotic spindle poleAurora kinase AHomo sapiens (human)
glutamatergic synapseAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
chromosome passenger complexAurora kinase AHomo sapiens (human)
spindle midzoneAurora kinase AHomo sapiens (human)
kinetochoreAurora kinase AHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (331)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID289691Antibacterial activity against Salmonella enteritidis at 40 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1125365Antibacterial activity against Staphylococcus aureus RN4220 assessed as growth inhibition at 240 ug/ml after 16 hrs by spectrophotometric analysis2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and antibacterial evaluation of amino acid-antibiotic conjugates.
AID454753Antileishmanial activity against Leishmania infantum MCAN/ES/92/BCN 83 promastigotes at 100 ug/ml after 48 hrs by resazurin method2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID251703Zone of inhibition of Klebsiella pneumoniae at compound concentration of 160 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1145680Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID649895Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID309230Antibacterial activity against Vibrio sp. after 24 hrs by disk diffusion method2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis, structure analysis, and antibacterial activity of some novel 10-substituted 2-(4-piperidyl/phenyl)-5,5-dioxo[1,2,4]triazolo[1,5-b][1,2,4]benzothiadiazine derivatives.
AID1125378Antibacterial activity against Staphylococcus aureus RN4220 assessed as growth inhibition at 120 ug/ml after 16 hrs by spectrophotometric analysis2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and antibacterial evaluation of amino acid-antibiotic conjugates.
AID284636Antibacterial activity against Bacillus subtilis MTCC 441 after 18 hrs2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Synthesis of a new class of 2-anilino substituted nicotinyl arylsulfonylhydrazides as potential anticancer and antibacterial agents.
AID1610407Selectivity ratio of CC30 for cytotoxicity against mouse L929 cells to IC50 for antiparasitic activity against Toxoplasma gondii RH infected in human Hs27 cells2019European journal of medicinal chemistry, Dec-15, Volume: 184Benzo[b]thiophene-thiazoles as potent anti-Toxoplasma gondii agents: Design, synthesis, tyrosinase/tyrosine hydroxylase inhibitors, molecular docking study, and antioxidant activity.
AID649902Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID478209Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 5 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID253053Antibacterial activity of compound against Escherichia coli at 20 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID70305Antibacterial activity against Escherichia coli at a concentration of 40 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1187272Antibacterial activity against Escherichia coli RCMB 010052 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID91140Effect of compound on percent survival of human fibroblast cells in culture was determined at 10 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID519621Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID344040Toxicity against human foreskin fibroblasts at 50 uM after 48 hrs by MTT method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID309226Antibacterial activity against Escherichia coli MTCC 448 after 24 hrs by disk diffusion method2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis, structure analysis, and antibacterial activity of some novel 10-substituted 2-(4-piperidyl/phenyl)-5,5-dioxo[1,2,4]triazolo[1,5-b][1,2,4]benzothiadiazine derivatives.
AID519618Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID313216Antiparasitic activity against Toxoplasma gondii infected african green monkey Vero cells at 20 mM assessed as infected cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids.
AID251674Zone of inhibition of Salmonella typhae at compound concentration of 40 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID247655Compound tested on vero cells infected with Toxoplasma gondii after 24 h2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Synthesis of thiosemicarbazone and 4-thiazolidinone derivatives and their in vitro anti-Toxoplasma gondii activity.
AID408579Aqueous solubility of compound at pH 7 by spectrophotometry2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID251679Zone of inhibition of Bacillus subtilis at compound concentration of 160 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID519617Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID557209Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis assessed as percent susceptible isolates by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID251697Zone of inhibition of Klebsiella pneumoniae at compound concentration of 40 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1125368Antibacterial activity against Staphylococcus aureus RN4220 assessed as growth inhibition at 60 ug/ml after 16 hrs by spectrophotometric analysis2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and antibacterial evaluation of amino acid-antibiotic conjugates.
AID511845Antimicrobial activity against tachyzoites of Toxoplasma gondii RH infected in Vero cells assessed as reduction of infected cells at 0.1 mM after 24 hrs relative to control2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles.
AID210626Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 0 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID64417Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.2 (Sauterne''s medium)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID519614Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1890860Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID70301Antibacterial activity against Escherichia coli at a concentration of 10 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID253056Antibacterial activity of compound against Bacillus subtilis at 10 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID284633Antibacterial activity against Escherichia coli MTCC 448 after 18 hrs2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Synthesis of a new class of 2-anilino substituted nicotinyl arylsulfonylhydrazides as potential anticancer and antibacterial agents.
AID344037Toxicity against human foreskin fibroblasts at 5 uM after 48 hrs by MTT method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID55867Inhibition of Escherichia coli (K12J53) Dihydopteroate synthase.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID309228Antibacterial activity against Klebsiella pneumoniae MTCC 618 after 24 hrs by disk diffusion method2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis, structure analysis, and antibacterial activity of some novel 10-substituted 2-(4-piperidyl/phenyl)-5,5-dioxo[1,2,4]triazolo[1,5-b][1,2,4]benzothiadiazine derivatives.
AID91141Effect of compound on percent survival of human fibroblast cells in culture was determined at 25 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID284634Antibacterial activity against Pseudomonas aeruginosa MTCC 424 after 18 hrs2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Synthesis of a new class of 2-anilino substituted nicotinyl arylsulfonylhydrazides as potential anticancer and antibacterial agents.
AID210629Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 5 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID519622Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID478201Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 5 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID649898Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1145674Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID670244Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microbroth dilution method2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Synthesis and antimycobacterial activity of some phthalimide derivatives.
AID1145688Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as active dose required to increase of 100% in mean survival time1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID649897Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1145687Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth in presence of p-aminobenzoic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID649909Antibacterial activity against methicillin-resistant Staphylococcus epidermidis H 6966/08 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID313218Inhibition of Toxoplasma gondii infected in african green monkey Vero cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids.
AID94203Antibacterial activity against Klebsiella pneumoniae at a concentration of 40 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1890853Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID445448Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID251698Zone of inhibition of Klebsiella pneumoniae at compound concentration of 80 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1145678Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1187266Antibacterial activity against Staphylococcus aureus RCMB 010028 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID478213Cytotoxicity against human CRL1634 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID599143Lipophilicity, log P of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID649903Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID247928Compound tested on intracellular parasites Toxoplasma gondii in vero cells after 24 h2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Synthesis of thiosemicarbazone and 4-thiazolidinone derivatives and their in vitro anti-Toxoplasma gondii activity.
AID343766Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID409949Inhibition of human liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID511850Antimicrobial activity against tachyzoites of Toxoplasma gondii RH infected in Vero cells assessed as reduction of infected cells after 24 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1145672Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID253052Antibacterial activity of compound against Escherichia coli at 10 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID649907Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID557208Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID289693Antibacterial activity against Pasteurella multocida at 30 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID289690Antibacterial activity against Salmonella enteritidis at 30 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID519612Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1187270Antibacterial activity against Enterococcus faecalis RCMB 010068 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID251962Zone of inhibition of Pseudomonas aeruginosa at compound concentration of 160 mg/mL; ND denotes ''not determined''2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID251672Zone of inhibition of Bacillus subtilis at compound concentration of 80 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID478211Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 25 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID70307Antibacterial activity against Escherichia coli at a concentration of 80 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID649901Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID251681Zone of inhibition of Salmonella typhae at compound concentration of 160 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1890852Antibacterial activity against Klebsiella pneumoniae assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1890855Antibacterial activity against Staphylococcus aureus assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1610408Antiparasitic activity against Toxoplasma gondii ME49 tachyzoites infected in human Hs27 cells assessed as inhibition of parasitic growth preincubated for 24 hrs followed by [5,6-3H]uracil addition and measured after 72 hrs by liquid scintillation countin2019European journal of medicinal chemistry, Dec-15, Volume: 184Benzo[b]thiophene-thiazoles as potent anti-Toxoplasma gondii agents: Design, synthesis, tyrosinase/tyrosine hydroxylase inhibitors, molecular docking study, and antioxidant activity.
AID25817PKa value was measured1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID313219Inhibition of intracellular parasite Toxoplasma gondii2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids.
AID253057Antibacterial activity of compound against Bacillus subtilis at 20 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID251951Zone of inhibition of Pseudomonas aeruginosa at compound concentration of 80 mg/mL; ND denotes ''not determined''2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID289689Antibacterial activity against Salmonella enteritidis at 20 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID289692Antibacterial activity against Pasteurella multocida at 20 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID251700Zone of inhibition of Staphylococcus aureus at compound concentration of 80 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID309227Antibacterial activity against Pseudomonas aeruginosa MTCC 424 after 24 hrs by disk diffusion method2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis, structure analysis, and antibacterial activity of some novel 10-substituted 2-(4-piperidyl/phenyl)-5,5-dioxo[1,2,4]triazolo[1,5-b][1,2,4]benzothiadiazine derivatives.
AID1125399Antibacterial activity against Escherichia coli DH5alpha assessed as growth inhibition at 75 ug/ml after 16 hrs by spectrophotometric method2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and antibacterial evaluation of amino acid-antibiotic conjugates.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID599144Intrinsic solubility, log 1/S0 of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID405525Inhibition of aurora kinase A2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Recent developments in fragment-based drug discovery.
AID344038Toxicity against human foreskin fibroblasts at 10 uM after 48 hrs by MTT method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID478212Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 50 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID454754Antileishmanial activity against Leishmania infantum MCAN/ES/92/BCN 83 promastigotes after 48 hrs by resazurin method2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide.
AID519610Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID210630Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 50 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID454755Cytotoxicity against mouse J774 cells after 24 hrs by by resazurin reduction test2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide.
AID94081Antibacterial activity against Klebsiella pneumoniae at a concentration of 160 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID94079Antibacterial activity against Klebsiella pneumoniae at a concentration of 120 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID519624Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID649908Antibacterial activity against methicillin-resistant Staphylococcus epidermidis H 6966/08 after 24 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1890857Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID557394Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis assessed as percent resistant isolates by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID55868In vitro inhibition of Escherichia coli (K12J53) growth.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID26320pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID91142Effect of compound on percent survival of human fibroblast cells in culture was determined at 5 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID649905Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1145689Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as dose required to survivors for period of 60 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1125401Antibacterial activity against Escherichia coli DH5alpha assessed as growth inhibition at 40 ug/ml after 16 hrs by spectrophotometric method2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and antibacterial evaluation of amino acid-antibiotic conjugates.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID106805Compound was tested for the inhibition of malate dehydrogenase (MDH) at 200 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID91143Effect of compound on percent survival of human fibroblast cells in culture was determined at 50 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID519626Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID344039Toxicity against human foreskin fibroblasts at 25 uM after 48 hrs by MTT method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID253058Antibacterial activity of compound against Bacillus subtilis at 40 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID309231Antibacterial activity against Bacillus subtilis MTCC 441 after 24 hrs by disk diffusion method2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis, structure analysis, and antibacterial activity of some novel 10-substituted 2-(4-piperidyl/phenyl)-5,5-dioxo[1,2,4]triazolo[1,5-b][1,2,4]benzothiadiazine derivatives.
AID284635Antibacterial activity against Staphylococcus epidermidis MTCC 435 after 18 hrs2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Synthesis of a new class of 2-anilino substituted nicotinyl arylsulfonylhydrazides as potential anticancer and antibacterial agents.
AID1610381Antiparasitic activity against Toxoplasma gondii RH tachyzoites infected in human Hs27 cells assessed as inhibition of parasitic growth preincubated for 24 hrs followed by [5,6-3H]uracil addition and measured after 72 hrs by liquid scintillation counting 2019European journal of medicinal chemistry, Dec-15, Volume: 184Benzo[b]thiophene-thiazoles as potent anti-Toxoplasma gondii agents: Design, synthesis, tyrosinase/tyrosine hydroxylase inhibitors, molecular docking study, and antioxidant activity.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID253059Antibacterial activity of compound against Bacillus subtilis at 80 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID40929Antibacterial activity against Bacillus subtilis at a concentration of 160 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1145677Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID313217Inhibition of uninfected african green monkey Vero cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID519625Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID649904Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 24 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID280386Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.
AID519613Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID251706Zone of inhibition of Staphylococcus aureus at compound concentration of 160 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID253054Antibacterial activity of compound against Escherichia coli at 40 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID91139Effect of compound on percent survival of human fibroblast cells in culture was determined at 0 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1125400Antibacterial activity against Escherichia coli DH5alpha assessed as growth inhibition at 50 ug/ml after 16 hrs by spectrophotometric method2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and antibacterial evaluation of amino acid-antibiotic conjugates.
AID343764Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 25 uM after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID210628Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 25 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID478210Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 10 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID519615Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID557210Antibacterial activity against Beta-lactamase-negative Neisseria meningitidis assessed as percent intermediate isolates by Etest method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
AID253055Antibacterial activity of compound against Escherichia coli at 80 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID511847Antimicrobial activity against tachyzoites of Toxoplasma gondii RH infected in Vero cells assessed as reduction of infected cells at 10 mM after 24 hrs relative to control2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles.
AID343762Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 5 uM after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1890856Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID13311Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID511849Cytotoxicity against african green monkey Vero cells infected with tachyzoites of Toxoplasma gondii RH after 24 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles.
AID251665Zone of inhibition of Escherichia coli at compound concentration of 40 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID284637Antibacterial activity against Vibrio species after 18 hrs2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Synthesis of a new class of 2-anilino substituted nicotinyl arylsulfonylhydrazides as potential anticancer and antibacterial agents.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID253064Antibacterial activity of compound against Klebsiella pneumoniae at 20 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID649892Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID253066Antibacterial activity of compound against Klebsiella pneumoniae at 80 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID1610380Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019European journal of medicinal chemistry, Dec-15, Volume: 184Benzo[b]thiophene-thiazoles as potent anti-Toxoplasma gondii agents: Design, synthesis, tyrosinase/tyrosine hydroxylase inhibitors, molecular docking study, and antioxidant activity.
AID94205Antibacterial activity against Klebsiella pneumoniae at a concentration of 80 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1890861Antibacterial activity against Acinetobacter baumannii assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID649896Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID313214Antiparasitic activity against Toxoplasma gondii infected african green monkey Vero cells at 5 mM assessed as infected cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1890859Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID313215Antiparasitic activity against Toxoplasma gondii infected african green monkey Vero cells at 8 mM assessed as infected cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids.
AID649899Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID210627Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 10 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID519619Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1610409Selectivity ratio of CC30 for cytotoxicity against mouse L929 cells to IC50 for antiparasitic activity against Toxoplasma gondii Me49 infected in human Hs27 cells2019European journal of medicinal chemistry, Dec-15, Volume: 184Benzo[b]thiophene-thiazoles as potent anti-Toxoplasma gondii agents: Design, synthesis, tyrosinase/tyrosine hydroxylase inhibitors, molecular docking study, and antioxidant activity.
AID251675Zone of inhibition of Salmonella typhae at compound concentration of 80 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1187269Antibacterial activity against Streptococcus pneumoniae RCMB 010010 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID478203Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 25 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID478204Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 50 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1187271Antibacterial activity against Staphylococcus aureus RCMB 010028 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID253065Antibacterial activity of compound against Klebsiella pneumoniae at 40 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID289694Antibacterial activity against Pasteurella multocida at40 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID251673Zone of inhibition of Escherichia coli at compound concentration of 160 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1145671Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID309229Antibacterial activity against Staphylococcus epidermidis MTCC 435 after 24 hrs by disk diffusion method2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis, structure analysis, and antibacterial activity of some novel 10-substituted 2-(4-piperidyl/phenyl)-5,5-dioxo[1,2,4]triazolo[1,5-b][1,2,4]benzothiadiazine derivatives.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID511848Cytotoxicity against african green monkey Vero cells after 24 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles.
AID1890858Antibacterial activity against Escherichia coli ATCC 25922 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID251699Zone of inhibition of Staphylococcus aureus at compound concentration of 40 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID478202Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 10 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1890854Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID649906Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 24 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID40931Antibacterial activity against Bacillus subtilis at a concentration of 40 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID253063Antibacterial activity of compound against Klebsiella pneumoniae at 10 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID343765Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 50 uM after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID313213Antiparasitic activity against Toxoplasma gondii infected african green monkey Vero cells at 2 mM assessed as infected cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID519611Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID90977Percentage growth inhibition of Toxoplasma gondii at concentration of 2 ug/mL using an human myelomonocytic cell line THP-12000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
Quinonic derivatives active against a virulent strain of Toxoplasma gondii. Synthesis of 2-methylfuro[2,3-g]- and [3,2-g]isoquinolinetriones.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID70303Antibacterial activity against Escherichia coli at a concentration of 20 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1187273Antibacterial activity against Salmonella typhimurium RCMB 010072 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID64418Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.41983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1187265Antibacterial activity against Enterococcus faecalis RCMB 010068 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID313212Antiparasitic activity against Toxoplasma gondii infected african green monkey Vero cells at 0.1 mM assessed as infected cells2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids.
AID251666Zone of inhibition of Escherichia coli at compound concentration of 80 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1187267Antibacterial activity against Escherichia coli RCMB 010052 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID519620Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-TOU infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1187264Antibacterial activity against Streptococcus pneumoniae RCMB 010010 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1187268Antibacterial activity against Salmonella typhimurium RCMB 010072 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID519623Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID251950Zone of inhibition of Pseudomonas aeruginosa at compound concentration of 40 mg/mL; ND denotes ''not determined''2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID40933Antibacterial activity against Bacillus subtilis at a concentration of 80 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID519616Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID511846Antimicrobial activity against tachyzoites of Toxoplasma gondii RH infected in Vero cells assessed as reduction of infected cells at 1 mM after 24 hrs relative to control2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID40927Antibacterial activity against Bacillus subtilis at a concentration of 120 ug/mL2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID649900Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID251671Zone of inhibition of Bacillus subtilis at compound concentration of 40 mg/mL2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1145675Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID343763Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 10 uM after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1803142Esterase Activity Assay from Article 10.3109/14756366.2011.617745: \\Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI.\\2012Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6
Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,975)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901868 (62.79)18.7374
1990's327 (10.99)18.2507
2000's252 (8.47)29.6817
2010's322 (10.82)24.3611
2020's206 (6.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.35 (24.57)
Research Supply Index8.11 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index167.07 (26.88)
Search Engine Supply Index2.60 (0.95)

This Compound (71.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials156 (4.91%)5.53%
Reviews124 (3.90%)6.00%
Case Studies341 (10.73%)4.05%
Observational4 (0.13%)0.25%
Other2,553 (80.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (24)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter, Randomized Clinical Trial to Compare the Efficacy and Tolerance of Prenatal Therapy With Pyrimethamine + Sulfadiazine vs Spiramycine to Reduce Vertical Transmission of Toxoplasma Gondii Following Primary Infection in Pregnancy [NCT01189448]Phase 3149 participants (Actual)Interventional2010-11-30Completed
Randomised Clinical Study to Evaluate the Use of Tilapia Skin (Oreochromis Niloticus), as an Occlusive Biological Dressing, in the Treatment of Burn Wounds [NCT03592498]Phase 263 participants (Actual)Interventional2016-10-05Completed
A Randomized Controlled Clinical Trial Comparing The Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine in the Treatment of Filipino Adults Aged 18-45 Years Old With Superficial Partial Thicknes [NCT02109718]Phase 350 participants (Actual)Interventional2009-01-31Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Phase I/II Clinical Trial Randomized, Multicentric, Open Label, Standard of Care (Silver Sulfadiazine) Controlled Aiming at Assessing Tolerance and Efficacy of Local Bacteriophage Treatment of Wound Infections Due to E. Coli or P. Aeruginosa in Burned Pat [NCT02116010]Phase 1/Phase 20 participants Interventional2015-07-31Recruiting
Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns [NCT03564795]30 participants (Anticipated)Interventional2018-08-31Recruiting
Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns [NCT02108535]Phase 4100 participants (Actual)Interventional2013-11-30Completed
Evaluation of a Management Strategy for Second-degree Fibrinous Burns Integrating a Poly-absorbent Dressing: a Prospective, Controlled, Open, Randomized Multicentre Study [NCT05347654]310 participants (Anticipated)Interventional2023-01-20Recruiting
Topical Collagen-Silver Versus Standard Care Following Phenol Ablation of Ingrown Nails: A Randomized Controlled Trial [NCT00641433]80 participants (Anticipated)Interventional2005-11-30Recruiting
Randomized Controlled Trial Assessing a Novel Glycopolymer Compound in the Treatment of Superficial Partial-Thickness Burns [NCT05877638]115 participants (Anticipated)Interventional2023-03-27Recruiting
A Randomized Intra-Patient Controlled Study of StrataXRT ® Versus Current Practice to Prevent and Treat Radiation Dermatitis [NCT05073172]92 participants (Anticipated)Interventional2024-01-01Not yet recruiting
A Phase 2, Open-Label, Randomized, Active-Controlled Pilot Study of Investigational Drug, MW-III Versus Silvadene® Cream 1% (Silver Sulfadiazine) Topically Applied to Second-Degree Thermal Burns in Adults [NCT01297400]Phase 260 participants (Anticipated)Interventional2022-03-11Recruiting
Evaluation of Nile Tilapia (Oreochromis Niloticus) Skin as an Occlusive Biological Dressing in the Treatment of Burn Wounds: Phase III Randomized Controlled Trial [NCT04202289]Phase 3115 participants (Actual)Interventional2017-04-03Completed
Randomized Controlled Trial Assessing a Novel Glycopolymer Compound in the Treatment of Superficial Partial-thickness Burns [NCT04601532]Phase 4115 participants (Anticipated)Interventional2021-06-11Recruiting
[NCT00372294]Phase 30 participants Interventional2005-07-31Active, not recruiting
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis [NCT00000794]Phase 2100 participants InterventionalCompleted
The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns [NCT00156988]Phase 40 participants Interventional2004-03-31Completed
The Clinical Efficacy of Epidermal Growth Factor With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream on Acceleration of Partial Thickness Burn Wound Healing [NCT01553708]Phase 2/Phase 334 participants (Actual)Interventional2011-12-31Completed
A Prospective Randomized Trial Comparing Silver Sulfadiazine Cream to a Water-Soluble Poly-Antimicrobial Gel in Partial Thickness Burn Wounds [NCT01926392]Phase 48 participants (Actual)Interventional2011-04-30Completed
Pediatric Burn Treatment Using Tilapia Skin as a Xenograft for Superficial-Partial Thickness Wounds: a Randomized Controlled Phase II Trial [NCT04391582]Phase 230 participants (Actual)Interventional2017-05-01Completed
Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis [NCT00004317]Phase 4600 participants (Anticipated)Interventional2000-07-31Recruiting
Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients: A Randomized Controlled Trial. [NCT00367081]Phase 430 participants Interventional2003-05-31Completed
Comparison Study OF Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Second Degree Burn [NCT03162367]Phase 240 participants (Actual)Interventional2019-04-10Completed
An Open, Randomized, Comparative, Multi-centre Investigation Evaluating the Efficacy and Tolerance of Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries. [NCT01439074]162 participants (Actual)Interventional2011-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01439074 (4) [back to overview]% of Study Burn Healed After One Week
NCT01439074 (4) [back to overview]Number of Dressing Changes
NCT01439074 (4) [back to overview]Percent of Burn Epithelised/Healed
NCT01439074 (4) [back to overview]Time to Healing
NCT01553708 (1) [back to overview]Time of Healing by Monitoring Duration (Days) at the Beginning of Treatment and the Day of Completely Epithelialization (Complete Epithelialization Means no Open Wound Exists as Confirmed by Two Surgeons).

% of Study Burn Healed After One Week

(NCT01439074)
Timeframe: 1 week

Interventionpercentage of study burn healed (Mean)
Mepilex Ag44.3
SSD Ag Cream27.0

[back to top]

Number of Dressing Changes

Number of dressing changes including first assembly (NCT01439074)
Timeframe: 4 weeks

Interventionapplications (Mean)
Mepilex Ag3.1
SSD Ag Cream14.0

[back to top]

Percent of Burn Epithelised/Healed

Healing will be defined as 95% or more epithelialisation (NCT01439074)
Timeframe: 4 weeks

Interventionpercentage of study burn healed (Mean)
Mepilex Ag87.1
SSD Ag Cream85.2

[back to top]

Time to Healing

Healing will be defined as number of days (NCT01439074)
Timeframe: 4 weeks

Interventiondays (Mean)
Mepilex Ag16
SSD Ag Cream17

[back to top]

Time of Healing by Monitoring Duration (Days) at the Beginning of Treatment and the Day of Completely Epithelialization (Complete Epithelialization Means no Open Wound Exists as Confirmed by Two Surgeons).

Time (days)for complete epithelialization (no open wound exists as determined by 2 surgeons) is the duration between the day of admission and the wound completely close without fluid leakage and are able to expose to environment without pain. (NCT01553708)
Timeframe: On 28th day after admission

InterventionDays (Mean)
Epidermal Growth Factor With Silver Sulfadiazine Cream23.06
Silver Zinc Sulfadiazine Cream30.94

[back to top]